DBVT
DBV TechnologiesNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.08B
P/E Ratio
—
EPS
$-4.50
Beta
-0.24
52W High
$26.18
52W Low
$7.53
50-Day MA
$20.10
200-Day MA
$16.92
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About DBV Technologies
DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products. The company is headquartered in Montrouge, France.
Fundamentals
| Revenue (TTM) | $5.74M |
| Gross Profit (TTM) | $5.74M |
| EBITDA | $-165.16M |
| Operating Margin | -5311.00% |
| Return on Equity | -158.90% |
| Return on Assets | -66.40% |
| Revenue/Share (TTM) | $0.13 |
| Book Value | $3.52 |
| Price-to-Book | 5.18 |
| Price-to-Sales (TTM) | 187.58 |
| EV/Revenue | 24.3 |
| EV/EBITDA | -2.07 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 12.50% |
| Shares Outstanding | $59.18M |
| Float | $176.27M |
| % Insiders | 0.00% |
| % Institutions | 37.12% |
Historical Volatility
HV 10-Day
33.90%
HV 20-Day
39.95%
HV 30-Day
45.67%
HV 60-Day
58.71%
HV Rank
4.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($40.48 target)
1
Strong Buy4
Buy1
SellMore HEALTHCARE Stocks
Data last updated: 5/25/2026